Evotec

#4929

Rank

$1.43B

Marketcap

Germany

Country

Leadership team

Dr. Werner Lanthaler M.B.A., MBA, MPA, Ph.D. (Chairman of Management Board & CEO)

Mr. Enno Spillner (CFO & Member of Management Board)

Dr. Cord Dohrmann Ph.D. (Chief Scientific Officer & Member of Management Board)

Products/ Services

Biopharma, Biotechnology, Pharmaceutical

Number of Employees

1,000 - 20,000

Headquarters

Hamburg, Hamburg, Germany

Established

1993

Company Registration

SEC CIK number: 0001412558

Revenue

500M - 1B

Traded as

EVO

Social Media

URL

https://www.evotec.com

Overview

Location

Recognition and Award

References

Summary

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

History

Evotec was founded in Hamburg, Germany in 1993 as a technology spin-off. Since then, it has completed more than fifty partnerships and alliances with the world’s leading pharmaceutical and biotechnology companies. It has grown to become one of the world’s leading biotechnology R&D companies, with more than 2,000 employees and operations in Europe, North America, and Asia.

Mission

Our mission is to discover, develop and help deliver innovative medicines that address major unmet medical needs of patients for the benefit of society.

Vision

Our vision is to become the leading drug discovery and development company, focused on hard-to-treat diseases, driven by scientific excellence and speed.

Key Team

Dr. Craig Johnstone (COO & Member of Management Board)

Dr. Matthias Evers (Chief Bus. Officer & Member of Management Board)

Dr. Christian Dargel (EVP Global Head of Legal & Compliance)

Ms. Anja Bosler (Principal Accounting Officer and Sr. VP of Group Accounting)

Mr. Volker Braun (Sr. VP and Global Head of Investor Relations & ESG)

Gabriele Hansen (Sr. VP & Head of Global Corp. Communications & Marketing)

Ms. Monika Conradt (Global Head of HR)

Recognition and Awards

Evotec has been the recipient of numerous awards over the years, including the Top Employer Award for 2019, and the Frost & Sullivan Best Practices Award for pharmacology in 2018.